Phase III study of tislelizumab in oesophageal squamous cell carcinoma meets primary endpoint

In the RATIONALE 302 trial (n=512), the anti-PD-1 monoclonal antibody was associated with ‘clinically meaningful’ improvements in overall survival compared to chemotherapy (paclitaxel, docetaxel or irinotecan). Detailed findings are due for presentation at an upcoming meeting.

Source:

Biospace Inc.